BCA
AERI

Berman Capital Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Berman Capital Advisors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-201
Closed -$4K – 1738
2019
Q4 		$4K Hold
201
– – ﹤0.01% 1063
2019
Q3 		$3K Buy
+201
New +$4.61K ﹤0.01% 1123

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Berman Capital Advisors's AERI Position: Q1 2020 in Review

Berman Capital Advisors sold out of Aerie Pharmaceuticals (AERI) in Q1 2020, closing a stake of 201 shares — an estimated $4K sold.

Berman Capital Advisors first reported a position in AERI in Q3 2019 and held it in 2 quarters. The position peaked at $4K in Q4 2019. 155 funds tracked by Wall St. Rank hold AERI as of Q1 2020.

  • Berman Capital Advisors reported no remaining Aerie Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Berman Capital Advisors sold 201 Aerie Pharmaceuticals shares in Q1 2020, an estimated $4K.
  • Berman Capital Advisors first reported a position in Aerie Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Berman Capital Advisors's Aerie Pharmaceuticals position peaked at $4K in Q4 2019.
  • 155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2020.

Based on Berman Capital Advisors's 13F filing for Q1 2020, filed 14 May 2020.